Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy

Intrahepatic cholangiocarcinoma (CCA), always diagnosed at an advanced stage in recent years, is of high aggression and poor prognosis. There is no standard treatment beyond first-line chemotherapy and no molecular-targeted agents or immune checkpoint inhibitors approved for advanced intrahepatic CC...

Full description

Bibliographic Details
Main Authors: Yuan Ding, Xin Han, Zhongquan Sun, Jinlong Tang, Yingsheng Wu, Weilin Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
advanced intrahepatic cholangiocarcinoma
systemic sequential therapy
surgery
conversion therapy
next-generation sequencing
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.691380/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.691380/full

Similar Items